Related Experiment Videos

[Is there a prognostic indication for PTCA?]

M P Heintzen1, C J Michel, U E Heidland

  • 1Medizinische Klinik und Poliklinik B Kardiologie, Pneumologie und Angiologie Heinrich-Heine-Universität, Düsseldorf.

Zeitschrift Fur Kardiologie
|October 29, 1998
PubMed

Insights

Percutaneous coronary intervention (PCI) is typically for symptomatic patients with ischemia. For asymptomatic patients, "prognostic indication" for PCI lacks large-scale evidence, requiring careful risk assessment.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Medicine

Background:

  • Coronary angioplasty is indicated for symptomatic patients with significant coronary stenosis and myocardial ischemia.
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) aims to alleviate symptoms and improve prognosis in these patients.
  • Coronary anatomy suitability is crucial for successful PTCA.

Purpose of the Study:

  • To define and evaluate the concept of "prognostic indication" for coronary angioplasty in asymptomatic patients.
  • To assess the current evidence and clinical considerations for using PTCA in asymptomatic individuals without proven ischemia.
  • To highlight the need for risk-benefit analysis in "prognostic indication" cases.

Main Methods:

  • Review of current clinical practice and literature regarding coronary angioplasty indications.
  • Analysis of the definition and application of "prognostic indication" in interventional cardiology.
  • Discussion of the evidence gap for PTCA in asymptomatic patients without ischemia.

Main Results:

  • "Prognostic indication" refers to interventional treatment of stenosis in asymptomatic patients without ischemia, aiming to improve prognosis.
  • Up to 20% of balloon angioplasty and 10% of stenting procedures may be performed under "prognostic indication".
  • No large-scale studies currently demonstrate a benefit of "prognostic indication" interventions in asymptomatic patients without ischemia.

Conclusions:

  • While "prognostic indication" is used, robust evidence supporting its benefit in asymptomatic patients without ischemia is lacking.
  • Certain subgroups might benefit from PTCA under "prognostic indication" compared to medical therapy alone.
  • Careful consideration of individual coronary disease risk versus procedural risk is essential for patients treated with "prognostic indication".

Related Concept Videos